2Q21 earnings presentation

Key topics Highest quarterly sales and earnings since spin-off, driven by strong US market recovery, new innovation and solid commercial execution ● Surgical franchise outperformed the market and Vision Care franchise returned to growth All sales categories posted growth vs. 2019, driven by market share gains Strong US market recovery in contrast to mixed international conditions Continuing investment in R&D and new contact lens manufacturing, and new product launches Raised full year 2021 guidance with projected net sales of $8.0 - $8.2 billion and core diluted EPS¹ of $2.00 - $2.10 Alcon 1. Core diluted EPS is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix. 5

View entire presentation